LFCR Quote, Financials, Valuation and Earnings

Cytokinetics, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of -15814.98%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Cytokinetics, Inc.'s return on equity of --.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 29.73%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $90.39 which suggests that it could grow by 33.04%. Given that Cytokinetics, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Cytokinetics, Inc. is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.589, which suggesting that the stock is 41.122% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.536, suggesting its less volatile than the S&P 500 by 46.407%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. Lifecore Biomedical, Inc.'s net income of -$10M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 1.92x versus 92.71x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inspire Medical Systems, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of 50.58%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Inspire Medical Systems, Inc.'s return on equity of 21.07%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 29.73%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $77.86 which suggests that it could grow by 30.79%. Given that Inspire Medical Systems, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Inspire Medical Systems, Inc. is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.589, which suggesting that the stock is 41.122% less volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.740, suggesting its less volatile than the S&P 500 by 26.041%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $269.1M. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Inspire Medical Systems, Inc.'s net income of $136.1M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Inspire Medical Systems, Inc.'s PE ratio is 11.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 1.92x versus 1.94x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings Corp. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of 10.3%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Integer Holdings Corp.'s return on equity of 6.11%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 29.73%. On the other hand Integer Holdings Corp. has an analysts' consensus of $90.86 which suggests that it could grow by 7.08%. Given that Lifecore Biomedical, Inc. has higher upside potential than Integer Holdings Corp., analysts believe Lifecore Biomedical, Inc. is more attractive than Integer Holdings Corp..

Lifecore Biomedical, Inc. has a beta of 0.589, which suggesting that the stock is 41.122% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.902%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Integer Holdings Corp. quarterly revenues of $472.1M. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Integer Holdings Corp.'s net income of $48.6M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Integer Holdings Corp.'s PE ratio is 29.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 1.92x versus 1.61x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of -1.41%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Molina Healthcare, Inc.'s return on equity of 10.89%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 29.73%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $157.56 which suggests that it could grow by 4.35%. Given that Lifecore Biomedical, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Lifecore Biomedical, Inc. is more attractive than Molina Healthcare, Inc..

Lifecore Biomedical, Inc. has a beta of 0.589, which suggesting that the stock is 41.122% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.546%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. Lifecore Biomedical, Inc.'s net income of -$10M is higher than Molina Healthcare, Inc.'s net income of -$160M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Molina Healthcare, Inc.'s PE ratio is 17.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 1.92x versus 0.18x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.